The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies
European Journal of Pharmaceutics and Biopharmaceutics · 2024
DOI: 10.1016/j.ejpb.2023.12.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024. Verfasst von Timothée Blin und 11 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Respiratory Disease Research Centre, U1100, F-37032 Tours, France; University of Tours, F-37032 Tours, France; Tours University Hospital (CHR…. Hauptthemen laut MEDLINE: Pneumonia, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Conseil Régional du Centre-Val de Loire.
Abstract (Originalsprache)
Like pneumonia, coronavirus disease 2019 (COVID-19) is characterized by a massive infiltration of innate immune cells (such as polymorphonuclear leukocytes) into the airways and alveolar spaces. These cells release proteases that may degrade therapeutic antibodies and thus limit their effectiveness. Here, we investigated the in vitro and ex vivo impact on anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) IgG1s and other IgG subclasses (IgG2 and IgG4) of the neutrophil elastase, proteinase 3 and cathepsin G (the three main neutrophil serine proteases) found in endotracheal aspirates from patients with severe COVID-19. Although the IgGs were sensitive to neutrophil serine proteases, IgG2 was most resistant to proteolytic degradation. The two anti-SARS CoV2 antibodies (casirivimab and imdevimab) were sensitive to the lung's proteolytic environment, although neutrophil serine protease inhibitors only partly limited the degradation. Overall, our results show that the pneumonia-associated imbalance between proteases and their inhibitors in the airways contributes to degradation of antiviral antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM, Respiratory Disease Research Centre, U1100, F-37032 Tours, France; University of Tours, F-37032 Tours, France; Tours University Hospital (CHRU), Department of Pulmonary Medicine, Cystic Fibrosis Resource Center,…
- INSERM, Respiratory Disease Research Centre, U1100, F-37032 Tours, France; University of Tours, F-37032 Tours, France.
- INSERM, Respiratory Disease Research Centre, U1100, F-37032 Tours, France; University of Tours, F-37032 Tours, France; Tours University Hospital (CHRU), Critical Care Department, F-37032 Tours, France.
- INSERM, Respiratory Disease Research Centre, U1100, F-37032 Tours, France; University of Tours, F-37032 Tours, France; Tours University Hospital (CHRU), Cardiac Surgery Department, F-37032 Tours, France.
- INSERM, Respiratory Disease Research Centre, U1100, F-37032 Tours, France; University of Tours, F-37032 Tours, France; Tours University Hospital (CHRU), Pharmacy Department, F-37032 Tours, France.
- University of Tours, F-37032 Tours, France; UMR INRA ISP 1282, BioMap Team, F-37032 Tours, France.
Förderung
- Agence Nationale de la Recherche
- Conseil Régional du Centre-Val de Loire
Zitieren
APA
Blin, T., Parent, C., Pichon, G., Guillon, A., Jouan, Y., Allouchi, H., Aubrey, N., Boursin, F., Domain, R., Korkmaz, B., Sécher, T., & Heuzé-Vourc'h, N. (2024). The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.12.003
Vancouver
Blin T, Parent C, Pichon G, Guillon A, Jouan Y, Allouchi H, et al. The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies. European Journal of Pharmaceutics and Biopharmaceutics. 2024. doi:10.1016/j.ejpb.2023.12.003
BibTeX
@article{Blin2024,
author = {Blin, Timothée and Parent, Christelle and Pichon, Gabrielle and Guillon, Antoine and Jouan, Youenn and Allouchi, Hassan and Aubrey, Nicolas and Boursin, Fanny and Domain, Roxane and Korkmaz, Baris and Sécher, Thomas and Heuzé-Vourc'h, Nathalie},
title = {The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2024},
doi = {10.1016/j.ejpb.2023.12.003}
}
EUVIMED